Comparison between multiparametric MRI with and without post - contrast sequences for clinically significant prostate cancer detection

• Published in: International Brazilian Journal of Urology Vol. 44; no. 6; pp. 1129 - 1138
• Main Authors: Mussi, Thais Caldara, Martins, Tatiana, Dantas, George Caldas, Garcia, Rodrigo Gobbo, Filippi, Renee Zon, Lemos, Gustavo Caserta, Baroni, Ronaldo Hueb
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Urologia 01.11.2018
• Subjects: Adult; Aged; Aged, 80 and over; Contrast Media - administration & dosage; Humans; Magnetic Resonance Imaging; Magnetic Resonance Imaging - methods; Male; Men; Middle Aged; Original; Predictive Value of Tests; Prostatic Neoplasms; Prostatic Neoplasms - diagnostic imaging; Sensitivity and Specificity; Magnetic Resonance Imaging; Prostatic Neoplasms; Men
• ISSN: 1677-5538; 1677-6119; 1677-6119
• DOI: 10.1590/S1677-5538.IBJU.2018.0102

Dynamic-contrast enhanced (DCE) sequence is used to increase detection of small lesions, based on increased vascularization. However, literature is controversy about the real incremental value of DCE in detection of clinically significant (CS) prostate cancer (PCa), since absence of enhancement does not exclude cancer, and enhancement alone is not definitive for tumor. To test the hypothesis that DCE images do not increase CS PCa detection on MRI prior to biopsy, comparing exams without and with contrast sequences. Material and Materials and Methods: All men who come to our institution to perform MRI on a 3T scanner without a prior diagnosis of CS PCa were invited to participate in this study. Reference standard was transrectal prostate US with systematic biopsy and MRI/US fusion biopsy of suspicious areas. Radiologists read the MRI images prospectively and independently (first only sequences without contrast, and subsequently the entire exam) and graded them on 5-points scale of cancer suspicion. 102 patients were included. Overall detection on biopsy showed CS cancer in 43 patients (42.2%), clinically non-significant cancer in 11 (10.8%) and negative results in 48 patients (47%). Positivities for CS PCa ranged from 8.9% to 9.8% for low suspicion and 75.0% to 88.9% for very high suspicion. There was no statistical difference regarding detection of CS PCa (no statistical difference was found when compared accuracies, sensitivities, specificities, PPV and NPV in both types of exams). Inter-reader agreement was 0.59. Exams with and without contrast-enhanced sequences were similar for detection of CS PCa on MRI.